Bayer’s Financial Crossroads: Legal Liabilities Overshadow Operational Performance

Bayer’s latest financial results present a stark dichotomy. While the company’s core business operations demonstrate resilience, its bottom line continues to be ravaged by billions in U.S. litigation costs. This persistent burden overshadows strategic efforts, such as the recent release of Phase III data for its new MRI contrast agent, Gadoquatrane. For investors, the pivotal question remains whether the corporation’s planned settlement payments can effectively contain the mounting pressure on its balance sheet and cash reserves.

A Deep Net Loss Mars Otherwise Stable Operations

For the 2025 fiscal year, Bayer reported group sales of €45.58 billion, marking a 2.2% decline. However, on a currency- and portfolio-adjusted basis, sales actually grew by 1.1%, indicating that operational performance is not the primary issue. The company’s adjusted EBITDA, which excludes special items, saw a moderate 4.5% decrease to €9.67 billion, a figure that slightly exceeded the average of analyst estimates.

The true damage is revealed in the net result. Bayer’s net loss ballooned to €3.62 billion, a significant widening from the prior year’s loss of €2.55 billion. This deterioration was primarily driven by special charges related to provisions for ongoing legal disputes in the United States.

The 2026 Forecast: Stable Sales but a Cash Flow Squeeze

Looking ahead to 2026, Bayer’s management has provided a currency-adjusted sales forecast ranging between €45 billion and €47 billion, implying growth of 0% to 3%. The outlook for adjusted EBITDA before special items is set at €9.6 billion to €10.1 billion, which sits below the 2025 level of €9.67 billion. CFO Wolfgang Nickl anticipates that stronger contributions from the Crop Science division and the consumer health (OTC) business will help offset a weaker performance in Pharmaceuticals.

A more critical concern for shareholders is the cash flow impact. The company has earmarked approximately €5 billion for legal settlement payments in 2026. Consequently, Bayer projects a negative free cash flow in the range of minus €1.5 billion to minus €2.5 billion. This outflow is expected to increase net financial debt from just under €30 billion to as much as €33 billion. Reflecting this constrained financial position, the dividend will remain at a low level, with a proposal of €0.11 per share for the Annual Stockholders’ Meeting on April 24, 2026.

Should investors sell immediately? Or is it worth buying Bayer?

Market sentiment reflects this uncertainty. Although shares gained 1.08% in a recent session to trade at €38.00, they have declined by 15.75% over a 30-day period. The stock’s Relative Strength Index (RSI) reading of 19.6 underscores the intensity of recent selling pressure.

Innovation Pipeline Contrasts with Persistent Legal Headwinds

The company’s strategic efforts are being pulled in two opposing directions. On one side, the massive legal overhang from U.S. glyphosate and PCB litigation continues to act as a major drag. Provisions and liabilities for these legal matters climbed to €11.8 billion by the end of 2025 as Bayer works toward resolutions.

Simultaneously, management is striving to highlight innovation. At the European Congress of Radiology (ECR 2026) in Vienna, Bayer unveiled new data from the pivotal Phase III program for Gadoquatrane. The investigational agent is a low-dose MRI contrast medium studied at a gadolinium dose of 0.04 mmol Gd/kg. According to the company, this represents a 60% reduction compared to the standard 0.1 mmol Gd/kg dose of macrocyclic GBCAs. Marketing applications for the product are currently under review in several key markets, including Japan, the U.S., the European Union, and China.

Ultimately, the investment narrative is split. Positive developments, such as growth in corn seed within the Crop Science division, provide glimmers of hope. Yet, the sheer scale of legal risk continues to severely limit the group’s financial flexibility.

All eyes now turn to the Annual Stockholders’ Meeting scheduled for April 24, 2026. The event will serve as a key milestone where the proposed dividend will be formally put to a vote. More importantly, Bayer’s leadership will be compelled to articulate a clear strategy for navigating the challenges of negative cash flow projections and rising debt, all stemming from its costly legal settlements.